First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments.

Keytruda (pembrolizumab) - Merck (MSD)

NG-350A - Akamis Bio

http://www.ncbi.nlm.nih.gov/pubmed/39414325

Andrea Stacey; Aung Naing; D Ross Camidge; Danny Khalil; Lee Rosen; Matthew Thomas; Oliver Rosen; Rui-Ru Ji; Tom Lillie

Oct 17, 2024